Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

The need to strengthen laboratory leadership, systems, and networks to enhance outbreak detection and resilience in Africa: proceedings of a regional workshop.

BMC proceedings·2026
Same author

Clonal expansion of global pneumococcal sequence cluster 3 within serotype 8 after 13-valent pneumococcal conjugate vaccine introduction, South Africa.

Microbial genomics·2026
Same author

Public Health Response to Toxigenic Respiratory Diphtheria Outbreaks at Correctional Facility, South Africa, 2023-2025.

Emerging infectious diseases·2026
Same author

Oropouche virus: transmission, epidemiology, genetic diversity, and public health implications.

EClinicalMedicine·2026
Same author

Identification and genomic characterization of BA.3.2: a highly divergent BA.3-related SARS-CoV-2 lineage from southern Africa.

Virus evolution·2026
Same author

Serotype-specific pneumococcal invasiveness: a global meta-analysis of paired estimates of disease incidence and carriage prevalence.

The Lancet. Microbe·2026

関連する実験動画

Updated: Jun 4, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

臨床的介入への反応として,肺炎球菌の急速な進化.

Nicholas J Croucher1, Simon R Harris, Christophe Fraser

  • 1The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, UK.

Science (New York, N.Y.)
|January 29, 2011
PubMed
まとめ
この要約は機械生成です。

Streptococcus pneumoniaeのゲノム性可塑性は,迅速な適応を可能にしています. この細菌の病原体は頻繁に再結合し,耐性や免疫回避の急速な進化を可能にし,公衆衛生の介入に影響を与えます.

さらに関連する動画

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae
09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

関連する実験動画

Last Updated: Jun 4, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae
09:12

Characterization of Inflammatory Responses During Intranasal Colonization with Streptococcus pneumoniae

Published on: January 17, 2014

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

科学分野:

  • 微生物学 微生物学とは
  • ゲノミクスゲノミクスとは
  • エピデミオロジー エピデミオロジー

背景:

  • Streptococcus pneumoniaeのような自然に変形可能な細菌病原菌は,高い再結合率のため,疫学研究において課題を提示しています.
  • 真の突然変異と水平遺伝子の移転を区別することは,細菌の進化を理解するために極めて重要です.

研究 の 目的:

  • ストレプトコッカス肺炎菌 (Streptococcus pneumoniae) の多剤耐性PMEN1系統のゲノム性可塑性と進化動態を調査する.
  • 塩基置換と再結合のイベントを,大規模な単離集合で区別する.

主な方法:

  • PMEN1系統から分離された240個のStreptococcus pneumoniaeの全ゲノム配列決定.
  • リコンビネーションイベントと塩基置換を特定し,定量化するために,配列データの分析.
  • 抗菌剤耐性およびカプセル交換に関連する遺伝子変化の追跡.

主要な成果:

  • 配列化された単離体内で700以上の再結合イベントが検出されました.
  • 主要抗原をコードする遺伝子は,10つのカプセル交換イベントを含む再結合によって頻繁に影響を受けました.
  • フルオロキノロン,リファンピシン,マクロリドに対する耐性の複数の独立した進化が観察されました.
  • カプセル交換イベントは,ワクチン導入後の米国でのワクチン脱出血清型19Aの出現と相関しています.

結論:

  • Streptococcus pneumoniaeのゲノム性可塑性は,臨床介入を含む選択的圧力への迅速な適応を促進する.
  • 再結合細菌は,短期間で耐性や免疫回避戦略を進化させることができます.
  • これらの進化的動態を理解することは,細菌の病原体に対する効果的な制御戦略の開発に不可欠です.